Project Grant R03AI188332
Award Date
7/16/25
Completion Date
6/30/27
Dollars Obligated
$152K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Drexel University (XF3XM9642N96)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Pensilvania, EE. UU.
Similar Awards
This federal Project Grant award of $191,300 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) supports research on modular, degradable, polymeric nanoparticles for the treatment of phagocyte-mediated diseases. The 4-year award, which commenced on Jul 4, 2025, aims to enable the principal investigator, Dr. Thomas C. Binns, MD, to develop expertise in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $501,011.00 to the University of North Carolina at Chapel Hill to conduct research on biodegradable polymeric microparticles comprised of acetalated dextran and their ability to induce immune tolerance. The goal is to develop an antigen-specific tolerance therapy for autoimmune diseases, an alternative to general...
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of polymer-phage nanoparticle conjugates to treat antibiotic-resistant wound biofilm infections. The $593,860 award to the University of Massachusetts aims to create new phage-polymer nanoparticles that can more effectively penetrate and eradicate bacterial biofilms compared to free phage therapies. The...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $160,000 in funding to Northwestern University to develop and evaluate engineered cytokine constructs that target lipid-laden macrophages for the treatment of atherosclerosis. The key objectives are to: 1) elucidate the molecular mechanisms by which the engineered cytokine constructs suppress inflammation in...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $413,542 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of North Carolina at Charlotte. The 2-year grant, effective August 1, 2025, will fund research to develop a novel nanoparticle-based therapeutic approach for targeting glial cells in the central nervous system. The goal is to limit both intracellular bacterial burden and glia-driven neuroinflammation during...
This federal Project Grant award of $425,226.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to establish the feasibility of engineering "trained innate immunity" using biomaterial implants. The research project, conducted by the Regents of the University of Michigan, will investigate how scaffold properties like pore size and degradation time can modulate the innate...
This federal Project Grant award of $350,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop polymer-derived biomaterials for messenger RNA (mRNA) delivery to induce antigen-specific immune tolerance. The award supports research to evaluate diverse nanocarrier formulations encapsulating antigens and mRNAs encoding tolerogenic proteins, investigate the biodistribution and...
The National Institute of General Medical Sciences (NIGMS) awarded a $754,625 Project Grant under the Biomedical Research and Research Training (CFDA 93.859) federal grant program to the University of Florida. The grant, effective September 1, 2024 through June 30, 2029, will fund research to understand the interaction between ultra-small nanoparticles (USNPs) and myeloid cells, such as inflammatory monocytes, and how myeloid cell trafficking can be leveraged to improve the targeting of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $244,440 to the Albert Einstein College of Medicine to investigate the mechanisms by which LY6C+ monocytes respond to and help clear microbial pathogen infections. The research aims to define the chemotactic cues, receptors, and molecular processes involved in how these monocytes home to infection sites and form stable...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $158,500 to Temple University to conduct an exploratory study on a new pH-responsive, ionizable hybrid nanocarrier for enhancing drug accumulation in bacterial biofilms. The goal is to develop and evaluate a novel nanocarrier design that can selectively target and penetrate biofilms, which are a major challenge...